SPEAKER 1: In both our European and our American guidelines, ECP is recommended as first line therapy in patients with erythrodermic cutaneous T-cell lymphoma. This includes mycosis fungoides and patients with Sézary syndrome. It can be used on its own, but because of the nature of the treatment, and that it's very safe, it can also be combined with other treatments to try and improve the efficacy of the treatment. It's often combined with interferon or bexarotene. This can be known as triple therapy.